HC Wainwright downgraded Vertex to "neutral" from "buy" and set an $85 price target. The firm said the company's 809 drug still has scientific risks.
UBS, on the other hand, increased its price target to $115 and set a "buy" rating. The firm said price, heterozygotes and takeout potential are all drivers of upside.
The stock was down 0.45% to $93.11 in pre-market trading on Wednesday.